ARCHIVES

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

This article is from The Cancer Letter archive.

Vol. 19 No. 02 | January 8, 1993

Download PDF Visit The Full Archive

Related Articles

Korn Revamps NCAB Committees, Names New Chairmen

October 5, 1984

Trials Approved by NCI CTEP For the Month of April

April 27, 2012

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

February 12, 1999

Adding Velcade Increased Overall Survival By 13.3 Months at Five-Year Analysis

December 30, 2011

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”

September 3, 1976